VYVGART Hytrulo 1,000 MG / 10,000 UNT in 5 ML Prefilled Syringe
- RxCUI
- 2712088
- RxNorm name
- VYVGART Hytrulo 1,000 MG / 10,000 UNT in 5 ML Prefilled Syringe
- Display name
- VYVGART Hytrulo 1,000 MG / 10,000 UNT in 5 ML Prefilled Syringe
- Full name
- VYVGART Hytrulo 1,000 MG / 10,000 UNT in 5 ML Prefilled Syringe
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:03
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761304 | Vyvgart Hytrulo | efgartigimod alfa and hyaluronidase-qvfc | 351(a) | Rx | 2026-09-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| VYVGART Hytrulo | EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) | argenx US | 7104d9e5-9910-47f5-9a93-741ac50f43b6 | 2026-07-15 | Warnings, Adverse reactions | 2712088 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 7104d9e5-9910-47f5-9a93-741ac50f43b6 | VYVGART Hytrulo 1,000 MG / 10,000 UNT in 5 ML Prefilled Syringe [PSN] · 5 ML efgartigimod alfa-qvfc 200 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Prefilled Syringe [Vyvgart Hytrulo] [SBD] · Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase-qvfc 1,000 MG / 10,000 UNT) per 5 ML Prefilled Syringe [SY] | 3 | 12 | These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO ® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023 | 20260513 |